SCD and metabolic disease: Therefore, as the rate-limiting enzyme that catalyzes the rate-limiting step for the conversion of SFA into MUFA, inhibition of SCD1 activity might ameliorate the metabolic disorders with less adverse effects caused by HFD in the future (48).